Royal North Shore Hospital

DoseMe Expands Global Footprint as Premier Hospitals and Cancer Centers across Australia Continue to Adopt Bayesian Dosing

Retrieved on: 
水曜日, 4月 17, 2024
Software, Pharmaceutical, Oncology, Health, Infectious Diseases, Hospitals, Health Technology, Technology, Mortality, Austin Hospital, Royal North Shore Hospital, Aminoglycoside, Hospital, Risk, Vancomycin, Safety, Research, Royal Perth Hospital, Attention, Acute kidney injury, HITRUST, Patient, Toxicity, AKI, Medicine, Algorithm, Pharmacist, Growth, Pharmaceutical industry

DoseMe , a leading provider of model-informed precision dosing (MIPD) software, is pleased to announce the continued growth in Australia.

Key Points: 
  • DoseMe , a leading provider of model-informed precision dosing (MIPD) software, is pleased to announce the continued growth in Australia.
  • The precision dosing software has informed over 400,000 dosing decisions, benefiting more than 10,000 patients and gaining the trust of over 1,000 clinicians nationwide.
  • “It is exciting to see the global demand around precision dosing, with Australia continuing to be a trailblazer,” said Paul Edwards, CEO of DoseMe.
  • This surge in clientele was boosted by strategic partnerships worldwide, underscoring DoseMe's commitment to global expansion and continuous innovation to deliver advanced precision dosing.

CARGO Therapeutics Announces Scientific Advisory Board

Retrieved on: 
水曜日, 12月 6, 2023
Associate, Baylor University, Baylor College of Medicine, Hospital, Division, Research, Investment company, Massachusetts General Hospital, MD, Doctor of Philosophy, SAB, SAN, Therapy, Cancer, CD2, Health, Section, Dana–Farber Cancer Institute, University, Hematology, Faculty, MBBS, Royal North Shore Hospital, Patient, Boston, Harvard Medical School, MGH, Medical school, CD22, Nursing

SAN MATEO, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CRGX), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the formation of a Scientific Advisory Board (SAB) comprised of distinguished experts in cancer research, immunology, and CAR T-cell therapy.

Key Points: 
  • SAN MATEO, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CRGX), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the formation of a Scientific Advisory Board (SAB) comprised of distinguished experts in cancer research, immunology, and CAR T-cell therapy.
  • The SAB will provide strategic counsel and critical expertise as CARGO advances its mission to develop the next generation of transformational CAR T-cell therapies.
  • “The SAB stands out by bringing together several highly accomplished translational investigators each with CAR T-cell experience that bridges both the laboratory and the clinic,” said Robbie Majzner, MD, co-founder of CARGO and Scientific Advisory Board Chair.
  • “They are uniquely suited to advise CARGO on their scientific goals and directions that will lead to better outcomes for patients.”
    Members of the CARGO Scientific Advisory Board are listed below; full bios are available on the CARGO website .

Global Coalition for Adaptive Research in Collaboration with Cure Brain Cancer Foundation Announce the Opening of Glioblastoma Clinical Trial in Australia

Retrieved on: 
火曜日, 11月 14, 2023
Science, Research, Pharmaceutical, Oncology, Health, Philanthropy, Clinical Trials, Foundation, AGILE, Radiation, Hope, Glioblastoma, GBM, Patient, Multimedia, Royal North Shore Hospital, Survival, Hospital, Global Coalition Against Pneumonia, Brain, Medical imaging, Pharmaceutical industry

The Global Coalition for Adaptive Research (GCAR) in collaboration with Cure Brain Cancer Foundation (CBCF), today announced the opening of GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment – NCT03970447) in Australia.

Key Points: 
  • The Global Coalition for Adaptive Research (GCAR) in collaboration with Cure Brain Cancer Foundation (CBCF), today announced the opening of GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment – NCT03970447) in Australia.
  • GBM AGILE is a revolutionary patient-centered, adaptive platform trial for registration that evaluates multiple therapies for patients with newly-diagnosed and recurrent glioblastoma (GBM) – the deadliest form of brain cancer.
  • “Cure Brain Cancer Foundation is an organization dedicated to rapidly improving brain cancer survival and ultimately finding a cure.
  • We are thrilled that patients in Australia will be able to participate in this innovative clinical trial,” said Lance Kawaguchi, CEO, Cure Brain Cancer Foundation.

Incredible World First Ribcage Implant Becomes 'alive'

Retrieved on: 
火曜日, 11月 16, 2021
X-ray, Neoplasm, Elective surgery, Tissue, Anatomical pathology, Infection, Tan Tock Seng Hospital, 3D, Technology, Royal North Shore Hospital, Porosity, Surgeon, Press release, Trauma, Cell, Patient, Ryukyu Kingdom, Medical imaging, Dentistry

StarPore® is a strong, flexible and porous material that allows the body's cells and tissues to grow into it -- unlike traditional, impermeable, implant materials.

Key Points: 
  • Previously surgeons used bone cement and wires to reconstruct the ribcage whilst the patient was on the operating table.
  • "StarPoreis unique because it becomes 'alive' within weeks, as the patient's own cells grow into the strong, flexible porous scaffold.
  • Anatomics is the pioneer of ribcage reconstruction having created the world's first 3D-printed ribcage for a Spanish patient in 2014.
  • The company has since perfected the technology leading to the first StarPore ribcage in being implanted in May 2019 in Singapore.

Incredible World First Ribcage Implant Becomes 'alive'

Retrieved on: 
火曜日, 11月 16, 2021
X-ray, Neoplasm, Elective surgery, Tissue, Anatomical pathology, Infection, Tan Tock Seng Hospital, 3D, Technology, Royal North Shore Hospital, Porosity, Surgeon, Press release, Trauma, Cell, Patient, Ryukyu Kingdom, Medical imaging, Dentistry

StarPore® is a strong, flexible and porous material that allows the body's cells and tissues to grow into it -- unlike traditional, impermeable, implant materials.

Key Points: 
  • Previously surgeons used bone cement and wires to reconstruct the ribcage whilst the patient was on the operating table.
  • "StarPoreis unique because it becomes 'alive' within weeks, as the patient's own cells grow into the strong, flexible porous scaffold.
  • Anatomics is the pioneer of ribcage reconstruction having created the world's first 3D-printed ribcage for a Spanish patient in 2014.
  • The company has since perfected the technology leading to the first StarPore ribcage in being implanted in May 2019 in Singapore.

FDA Grants Madorra Breakthrough Device Designation Status for Treatment of Moderate to Severe Vulvovaginal Atrophy

Retrieved on: 
水曜日, 9月 8, 2021
Women, Pharmaceutical, Managed Care, Health, FDA, Medical Devices, Consumer, Other Health, VVA, Madorra, VVA, MADORRA

The FDA has granted Madorra breakthrough device designation for the companys non-invasive, home-use device for a subset of women experiencing moderate to severe vulvovaginal atrophy (VVA), a component of genitourinary syndrome of menopause (GSM).

Key Points: 
  • The FDA has granted Madorra breakthrough device designation for the companys non-invasive, home-use device for a subset of women experiencing moderate to severe vulvovaginal atrophy (VVA), a component of genitourinary syndrome of menopause (GSM).
  • The designation is associated with priority review status for submissions relating to Madorras breakthrough device.
  • Under the Program, FDA will provide Madorra with priority review and communication regarding device development until the product is brought to market.
  • Madorra is developing its first product, as a prescription, non-invasive, home-use, handheld device.